Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure

@article{Lillyblad2015DualAR,
  title={Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure},
  author={Matthew P. Lillyblad},
  journal={Annals of Pharmacotherapy},
  year={2015},
  volume={49},
  pages={1237 - 1251}
}
  • M. Lillyblad
  • Published 14 July 2015
  • Medicine
  • Annals of Pharmacotherapy
Objective: To evaluate the clinical role of sacubitril/valsartan, a novel angiotensin–neprilysin inhibitor, for the treatment of chronic heart failure with a reduced ejection fraction (HFrEF). Data Sources: A search of PubMed was conducted using a combination of the search terms sacubitril, valsartan, LCZ696, neprilysin inhibition, natriuretic peptide system, renin-angiotensin system, and heart failure with reduced ejection fraction. Bibliographies of all retrieved articles were reviewed for… 

Figures and Tables from this paper

Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies

To conclude, sacubitril/valsartan significantly improved morbidity and mortality in patients with chronic HF, but it will need meticulous attention when used in real outpatient practice.

Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction

In the large, randomized, double-blind, PARADIGM-HF trial, sacubitril/valsartan reduced the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure significantly more than the angiotensin converting enzyme (ACE) inhibitor enalapril.

Cost-Effectiveness of SacubitrilValsartan in Patients With Heart Failure With Reduced Ejection Fraction

Treatment with sacubitrilvalsartan reduced cardiovascular mortality, decreased hospitalizations and emergency department (ED) visits for heart failure, and improved quality of life compared with enalapril therapy, according to an independent analysis of the cost-effectiveness.

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension

The results suggest limited effects of combination therapy with NEP inhibition and AT1R antagonism against AngII-induced hypertension, atherosclerosis, or AAAs and do not support this drug combination in therapy of these angiotensin II-induced cardiovascular diseases.

Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy

LCZ696 should be strongly considered as a favorable alternative to angiotensin converting enzyme inhibitors and ang Elliotensin receptor blockers in appropriate heart failure patients.

A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction

The place of therapy with ivabradine and sacubitril/valsartan is defined by these trials and their interplay with guideline‐directed medical therapy.

Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany

A post hoc analysis of the cost effectiveness, budget impact, and disease burden reduction of sacubitril/valsartan compared with ACE inhibitors for patients with heart failure from the perspective of the German social health insurance (SHI).

Novel Agent, Sacubitril-Valsartan: Prescribing Patterns and Perceived Barriers to Hospital Formulary Inclusion

It was discovered that the most prominent barrier to approval for many institutions is the price discrepancy between standard heart failure and new drug formulary.

▼ Sacubitril valsartan for heart failure

The evidence for sacubitril valsartan is reviewed and its place in the management of heart failure is considered.

References

SHOWING 1-10 OF 69 REFERENCES

Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction

In the large, randomized, double-blind, PARADIGM-HF trial, sacubitril/valsartan reduced the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure significantly more than the angiotensin converting enzyme (ACE) inhibitor enalapril.

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotens in-converting enzyme inhibition.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.

Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)

Omapatrilat reduces the risk of death and hospitalization in chronic heart failure but was not more effective than ACE inhibition alone in reducing therisk of a primary clinical event.

Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy

LCZ696 should be strongly considered as a favorable alternative to angiotensin converting enzyme inhibitors and ang Elliotensin receptor blockers in appropriate heart failure patients.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination.

Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Felodipine exerts a well-tolerated additional sustained vasodilator effect in patients with heart failure treated with enalapril, but the only possible long-term benefit was a trend for better exercise tolerance and less depression of quality of life in the second year of treatment.
...